



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Travel Medicine and Infectious Disease

journal homepage: www.elsevier.com/locate/tmaid

Editorial

Learning from SARS and MERS: COVID-19 reinfection where do we stand?

In the last 20 years, we had witnessed the emergence of the Severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), initially reported from Guangdong province, China in 2002, the Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) from Jeddah, Saudi Arabia, in 2012 and SARS-CoV-2 in December 2019 in Wuhan, Hubei province in China. SARS-CoV-2 had caused an ongoing global pandemic of COVID-19 (COroNaVirus Disease-2019). These viruses are genetically related to the circulating seasonal human coronaviruses: alphacoronaviruses, NL63 and 229E, and betacoronaviruses, HKU1 and OC43. Coronaviruses, mainly NL63 or 229E, show a seroprevalence of 75% and 65% in children by 2.5–3.5 years of age [1]. In addition, these seasonal coronaviruses are the etiology of respiratory infection in 22–25% of adults with acute respiratory illness [2,3]. The occurrence of reinfection with OC43 is at least partially attributed to genetic substitution in the potential cleavage site sequence of the spike protein [4].

Since the emergence of COVID-19, it has been debated and discussed whether it is possible or frequent to have reinfection. It is a real possibility and it would be a major threat to the current measures to control the COVID-19 pandemic if there is a significant variants. In a recent commentary, three questions were posed regarding reinfection with SARS-CoV-2. These questions are: how common is reinfection? how severe are reinfections? and what does reinfection mean for vaccines? [5]. A positive SARS-CoV-2 PCR after resolution of symptoms and a negative PCR may not indicate reinfection [6]. A true positive SARS-CoV-2 by PCR may indicate: persistence of non-viable RNA after the first episode, reinfection, or a relapse [7–9]. The mean time to negative SARS-CoV-2 RT-PCR was 24 days after symptom onset and 10% were positive at 33 days after symptom onset [10].

In a small study of 12 patients who had recurrent infection with common coronaviruses, the median time to reinfection was 37 weeks (4–48 weeks) and 9 of those patients had reinfection with OC43 and reinfection episode was milder [11]. In another study, 8.5% of 470 patients had reinfection with new or the same coronavirus occurring 566 and 676 days, respectively [12].

SARS pandemic was controlled easily and did not extend in time. Thus, it might had not been possible to examine whether reinfection is a real possibility or not. Despite, the extended occurrence of MERS-CoV cases since 2012, there is no clinical data on MERS reinfection. In a rabbit model, reinfection was associated with enhanced pulmonary inflammation, without an increase in viral RNA titers [13].

In a rhesus macaque model of SARS-CoV-2 infection, a rechallenge with an identical SARS-CoV-2 strain in the early recovery phase was not associated with viral dissemination, clinical manifestations, or histopathological changes [14]. However, the study did not look at a different strain and did not examine the possibility of reinfection months after

initial challenge as the reinfection was done at day 28 of the first infection [14].

There are few studies showing that positive SARS-CoV-2 may continue 20–22 days from onset of symptoms and few patients may have positive results up to 44 days [15–17]. A pregnant woman had positive SARS-CoV-2 PCR up to 104 days after initial infection [18]. In a case series, asymptomatic patients had repeat positive RT-PCR 5- and 13-days post negative testing [7].

In one study, there were three patients who were proposed to have been reinfected [19]. The interval between the two infections was between 22 and 41 days and two patients had positive culture at the second episode and an identified B1 (European) lineage, according to the Pangolin classification [19,20]. Another patient was classified to have reinfection three months apart. Full-length genome sequencing showed initial infection was due to a lineage B.1.1 and relapsing infection by a lineage A SARS-CoV-2 [21].

In a patient from Hong Kong, he was reported to have SARS-CoV-2 reinfection 4.5 months after the first infection [22]. He initially had symptomatic COVID-19 with cough, sore throat, fever and headache for three days and tested positive March 26, 2020. He recovered and upon a travel-related screening, he tested positive on returning to Hong Kong from Spain via the United Kingdom on August 15, 2020. He was asymptomatic and genetic analysis showed that the first infection was caused by SARS-CoV-2 strain closely related to strains from the United States or England, and the second infection was most closely related to strains from Switzerland and England with 24-nucleotide difference [22]. Sequence analysis is important in this case as it excluded the possibility of persistent or re-appearance of positive SARS-CoV-2 after initial negative test, a phenomenon that is described as intermittent SARS-CoV-2 test [23]. However, it is important to note that the two infections occurred 4.5 months apart and that the second infection was asymptomatic. In addition, the first infection was not associated with the appearance of anti-SARS-CoV-2 antibodies whereas the second infection elicited antibody response. An additional case of possible SARS-CoV-2 reinfection was suspected in a patient from Peru [24].

Two healthcare workers were reported to have asymptomatic reinfections within 3.5 months of the first infection [25]. In these patients, the genome sequencing revealed 9–10 unique variant differences between the virus isolates from the two episode [25]. Another reinfection was reported within 2 months in a healthcare worker [26]. One case of reinfection was thought to occur within 1 month [27]. In a case series and systematic review, a total of 1359 cases were presumed to have reactivation/reinfection [28]. This occurrence was observed in a mean days of 34.5 after initial COVID-19 infection and 5.6% had fever and 27.6% symptoms [28]. In 6 of 9 such cases, the virus was not cultured in

<https://doi.org/10.1016/j.tmaid.2021.102024>

Received 14 October 2020; Received in revised form 26 February 2021; Accepted 9 March 2021

Available online 16 March 2021

1477-8939/© 2021 Elsevier Ltd. All rights reserved.

the second infection [28]. However, these cases were more a persistent PCR positivity rather than a reinfection. In a recent case from Nevada, USA, a 25-year-old male re-tested positive for a second but distinct SARS-CoV-2 variant from the initial infection after two negative SARS-CoV-2 tests [29]. The second infection occurred 48 days after the first infection and was more severe than the first infection [29]. In a patient from Ecuador, he had re-infection 10 weeks apart with two clades (B.1.p9 GISAID and A.1.1 GISAID) [30].

An immunocompromised patient was thought to have two COVID-19 episodes 59 days apart [31]. There were no negative samples in between the two episodes and the two strains differed at ten nucleotide positions [31]. This difference was thought to be enough to classify the second episode as a re-infection and the patient died 2 weeks in her second illness [31].

The duration of SARS-specific IgG was reported in 176 patients and showed that these antibodies were maintained for a mean of two years with significant reduction of titers the third year [32]. In another study of 623 SARS patients, neutralizing IgG antibodies peaked at 20–30 days and were sustained for >150 days [33]. A third study showed that SARS neutralizing antibodies appeared in the second week, peaked during week 4, and persisted in some patients for >200 days after onset of fever [34]. Additionally, one study showed that anti-nucleocapsid protein IgG antibody were positive at day 240 [35]. In a study of 56 SARS patients, neutralizing antibodies peaked at 4th month after the onset of disease and were undetectable in 11.8% of patients at month 24 [36]. In 18 patients with SARS, IgG titer peaked on day 60, and remained high until day 180 and decreased gradually until day 720 [37]. Anti-SARS IgG antibodies remained positive in 17 patients at 12 months [38].

What about the response to MERS-CoV infection? There are limited studies of persistence of neutralizing antibodies after MERS-CoV infection. In one study of 7 patients, neutralizing antibodies were detectable in 86% for at least 34 months [39]. Thus, neutralizing antibodies against MERS persist for a longer duration than those reported for SARS-CoV-2.

SARS-CoV-2 antibodies decline within 8 weeks [40,41]. In addition, asymptomatic or mildly symptomatic patients may not develop antibodies. In one study, 40% of asymptomatic and 12.9% of symptomatic individuals became seronegative for IgG in the early convalescent phase [41]. Thus, it is presumed that individuals become vulnerable to reinfection over time. This has implications for building herd immunity and effectiveness of developed vaccines. However, it is important to note that antibody response is not the only immune response for protection and T-cell immune response is also important. Antibodies may help in neutralizing viruses and killer T-cells help in destroying cell-infected with viruses. While neutralizing antibodies could prevent an infection from occurring, T-cells deal with established infection and facilitate a robust antibody cell response and maturation.

Thus, the data suggest that neutralizing antibodies in SARS and MERS patients last longer than those in COVID-19 patients. As expected, the developed immunity is partial and individuals could get reinfected. However, the reported cases are sparse and these could not be generalized. Also, it is not known if the majority of the reinfection with SARS-CoV-2 would be of the same, less, or more severity. These are important questions to be answered as we continue the battle against COVID-19 pandemic. The role that memory cells play is of paramount importance. The recent COVID-19 vaccinations such as those of Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca and the race to achieve community immunity are important to end this pandemic. However, the emergence of new variants and reports of evading the immune response [42] are additional burdens on the global immunization efforts. The recently emerged variants emerging in the United Kingdom, South Africa and Brazil are of particular concern. For example, SARS-CoV-2 B.1.1.7 variant is thought to be more transmissible than other variants. Additionally, these variants may not be covered by immune responses elicited by currently available vaccines. Reinfection with SARS-CoV-2 is a possibility, indicating that exposure to the virus may not translate to total immunity. Given the fact that >111 million, to

date, were infected with SARS-CoV-2, and with limited number of reported reinfections, it is not clear how significant a problem reinfection is likely to be. However, it is imperative that all individuals, whether previously diagnosed with COVID-19 or not should take identical precautions to avoid re-infection with SARS-CoV-2 till the time when community immunity had been achieved.

References

- [1] Dijkman R, Jebbink MF, El Idrissi NB, Pyrc K, Müller MA, Kuijpers TW, et al. Human coronavirus NL63 and 229E seroconversion in children. *J Clin Microbiol* 2008;46:2368–73. <https://doi.org/10.1128/JCM.00533-08>.
- [2] Ambrosioni J, Bridevaux PO, Wagner G, Mamin A, Kaiser L. Epidemiology of viral respiratory infections in a tertiary care centre in the era of molecular diagnosis, Geneva, Switzerland, 2011–2012. *Clin Microbiol Infect* 2014;20:0578–84. <https://doi.org/10.1111/1469-0691.12525>.
- [3] Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses. *J Med Virol* 2020;92:512–7. <https://doi.org/10.1002/jmv.25715>.
- [4] Vijgen L, Keyaerts E, Lemey P, Moës E, Li S, Vandamme AM, et al. Circulation of genetically distinct contemporary human coronavirus OC43 strains. *Virology* 2005;337:85–92. <https://doi.org/10.1016/j.viro.2005.04.010>.
- [5] Ledford H. Coronavirus reinfections: three questions scientists are asking. *Nature* 2020;585:168–9. <https://doi.org/10.1038/d41586-020-02506-y>.
- [6] Alvarez-Moreno CA, Rodríguez-Morales AJ. Testing Dilemmas: post negative, positive SARS-CoV-2 RT-PCR – is it a reinfection? *Trav Med Infect Dis* 2020;35. <https://doi.org/10.1016/j.tmaid.2020.101743>.
- [7] Dao TL, Hoang VT, Gautret P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review. *Eur J Clin Microbiol Infect Dis* 2021;40:13–25. <https://doi.org/10.1007/s10096-020-04088-z>.
- [8] Gao Z, Xu Y, Guo Y, Xu D, Zhang L, Wang X, et al. A systematic review of re-detectable positive virus nucleic acid among COVID-19 patients in recovery phase. *Infect Genet Evol* 2020;85. <https://doi.org/10.1016/j.meegid.2020.104494>.
- [9] Mattiuzzi C, Henry BM, Sanchis-Gomar F, Lippi G. Sars-cov-2 recurrent rna positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. *Acta Biomed* 2020;91:1–7. <https://doi.org/10.23750/abm.v91i3.10303>.
- [10] Gombor S, Chang M, Hogan CA, Zehnder J, Boyd S, Pinsky BA, et al. Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19. *J Clin Virol* 2020;129. <https://doi.org/10.1016/j.jcv.2020.104477>.
- [11] Galanti M, Shaman J. Direct observation of repeated infections with endemic coronaviruses. *J Infect Dis* 2020. <https://doi.org/10.1093/infdis/jiaa392>.
- [12] Ringlander J, Nilsson S, Westin J, Lindh M, Martner A, Hellstrand K. Low incidence of reinfection with endemic coronaviruses diagnosed by RT-PCR. *J Infect Dis* 2020. <https://doi.org/10.1093/infdis/jiaa627>.
- [13] Houser KV, Broadbent AJ, Gretebeck L, Vogel L, Lamirande EW, Sutton T, et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. *PLoS Pathog* 2017;13. <https://doi.org/10.1371/journal.ppat.1006565>.
- [14] Chandrashekar A, Liu J, Martino AJ, McMahan K, Mercad NB, Peter L, et al. SARS-CoV-2 infection protects against challenge in rhesus macaques. *Science* 2020;369:812–7. <https://doi.org/10.1126/science.abc4776>. 80–.
- [15] Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study. *J Clin Virol* 2020;127. <https://doi.org/10.1016/j.jcv.2020.104346>.
- [16] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;6736:1–9. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
- [17] Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR test results in patients recovered from COVID-19. *JAMA, J Am Med Assoc* 2020;323:1502–3. <https://doi.org/10.1001/jama.2020.2783>.
- [18] Molina LP, Chow SK, Nickel A, Love JE. Prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in an obstetric patient with antibody seroconversion. *Obstet Gynecol* 2020;136:838–41. <https://doi.org/10.1097/AOG.0000000000004086>.
- [19] Lafaie L, Célariet T, Goethals L, Pozzetto B, Grange S, Ojardias E, et al. Recurrence or relapse of COVID-19 in older patients: a description of three cases. *J Am Geriatr Soc* 2020;68:2179–83. <https://doi.org/10.1111/jgs.16728>.
- [20] Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol* 2020. <https://doi.org/10.1038/s41564-020-0770-5>.
- [21] Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B, Wollants E, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. *Clin Infect Dis* 2020. <https://doi.org/10.1093/cid/ciaa1330>.
- [22] To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. Coronavirus disease 2019 (COVID-19) Re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing. *Clin Infect Dis* 2020. <https://doi.org/10.1093/cid/ciaa1275>.
- [23] AlJishi JM, Al-Tawfiq JA. Intermittent viral shedding in respiratory samples of patients with SARS-CoV-2: observational analysis with infection control implications. *J Hosp Infect* 2020. <https://doi.org/10.1016/j.jhin.2020.09.011>.

- [24] Arteaga-Livias K, Panduro-Correa V, Pinzas-Acosta K, Perez-Abad L, Pecho-Silva S, Espinoza-Sánchez F, et al. COVID-19 reinfection? A suspected case in a Peruvian patient. *Trav Med Infect Dis* 2021;39. <https://doi.org/10.1016/j.tmaid.2020.101947>.
- [25] Gupta V, Bhojra RC, Jain A, Srivastava S, Upadhyay R, Imran M, et al. Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. *Clin Infect Dis* 2020. <https://doi.org/10.1093/cid/ciaa1451>.
- [26] Larson D, Brodnyak SL, Voegtly LJ, Cer RZ, Glang LA, Malagon FJ, et al. A case of early Re-infection with SARS-CoV-2. *Clin Infect Dis* 2020. <https://doi.org/10.1093/cid/ciaa1436>.
- [27] Bonifácio LP, Pereira APS, E Araújo DC de A, Balbão V da MP, da Fonseca BAL, Passos ADC, et al. Are sars-cov-2 reinfection and covid-19 recurrence possible? A case report from Brazil. *Rev Soc Bras Med Trop* 2020;53:1-4. <https://doi.org/10.1590/0037-8682-0619-2020>.
- [28] Gidari A, Nofri M, Saccarelli L, Bastianelli S, Sabbatini S, Bozza S, et al. Is recurrence possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of literature. *Eur J Clin Microbiol Infect Dis* 2020. <https://doi.org/10.1007/s10096-020-04057-6>.
- [29] Tillett RL, Sevensky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. *Lancet Infect Dis* 2020. [https://doi.org/10.1016/s1473-3099\(20\)30764-7](https://doi.org/10.1016/s1473-3099(20)30764-7).
- [30] Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, Marquez S, Gutierrez B, Rojas-Silva P, et al. COVID-19 Re-Infection by a phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America. *SSRN Electron J* 2020. <https://doi.org/10.2139/ssrn.3686174>.
- [31] Mulder M, van der Vegt DSJM, Oude Munnink BB, GeurtsvanKessel CH, van de Bovenkamp J, Sikkema RS, et al. Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report. *Clin Infect Dis* 2020. <https://doi.org/10.1093/cid/ciaa1538>.
- [32] Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of antibody responses after severe acute respiratory syndrome. *Emerg Infect Dis* 2007;13:1562-4. <https://doi.org/10.3201/eid1310.070576>.
- [33] Nie Y, Wang G, Shi X, Zhang H, Qiu Y, He Z, et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. *J Infect Dis* 2004;190:1119-26. <https://doi.org/10.1086/423286>.
- [34] Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, et al. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. *Emerg Infect Dis* 2005;11:411-6. <https://doi.org/10.3201/eid1103.040906>.
- [35] Woo PCY, Lau SKP, Wong BHL, Chan KH, Chu CM, Tsoi HW, et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. *Clin Diagn Lab Immunol* 2004;11:665-8. <https://doi.org/10.1128/CDLI.11.4.665-668.2004>.
- [36] Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. *J Infect Dis* 2006;193:792-5. <https://doi.org/10.1086/500469>.
- [37] Mo H, Zeng G, Ren X, Li H, Ke C, Tan Y, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. *Respirology* 2006;11:49-53. <https://doi.org/10.1111/j.1440-1843.2006.00783.x>.
- [38] Chang SC, Wang JT, Huang LM, Chen YC, Fang CT, Sheng WH, et al. Longitudinal analysis of severe acute respiratory syndrome (SARS) coronavirus-specific antibody in SARS patients. *Clin Diagn Lab Immunol* 2005;12:1455-7. <https://doi.org/10.1128/CDLI.12.12.1455-1457.2005>.
- [39] Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M, et al. Persistence of antibodies against middle east respiratory syndrome coronavirus. *Emerg Infect Dis* 2016;22:1824-6. <https://doi.org/10.3201/eid2210.160706>.
- [40] Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* 2020;584:437-42. <https://doi.org/10.1038/s41586-020-2456-9>.
- [41] Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* 2020;26:1200-4. <https://doi.org/10.1038/s41591-020-0965-6>.
- [42] Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Lambson BE, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. *BioRxiv Prepr Serv Biol* 2021. <https://doi.org/10.1101/2021.01.18.427166>.

Jaffar A. Al-Tawfiq*

Specialty Internal Medicine and Quality Department, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia

Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

Division of Infectious Diseases, Department of Medicine Johns Hopkins University School of Medicine, Baltimore, MD, USA

Ali A. Rabaan

Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia

Awad Al-Omari

Research Center, Dr. Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia

College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

Abbas Al Mutair

Research Center, Almoosa Specialist Hospital, Al Hasa, Saudi Arabia
College of Nursing, prince Nora University, Riyadh, Saudi Arabia

School of Nursing, Wollongong University, Australia

Manaf Al-Qahtani

Bahrain National Taskforce to Combat COVID-19, Bahrain Defense Force Hospital, Bahrain

Raghavendra Tirupathi

Penn State University School of Medicine, Hershey, PA, USA
Wellspan Chambersburg and Waynesboro (Pa.) Hospitals, Chambersburg, PA, USA

* Corresponding author.

E-mail addresses: jaffar.tawfiq@jhah.com, jaltawfi@yahoo.com (J.A. Al-Tawfiq).